Page last updated: 2024-10-21

urea and HIV Coinfection

urea has been researched along with HIV Coinfection in 38 studies

pseudourea: clinical use; structure
isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.

Research Excerpts

ExcerptRelevanceReference
"Tenofovir disoproxil fumarate (TDF) has been anecdotally associated with isolated hypophosphatemia (HP) as well as proximal tubular toxicity and renal dysfunction in which HP has consistently been a feature."7.73Serum hypophosphatemia in tenofovir disoproxil fumarate recipients is multifactorial in origin, questioning the utility of its monitoring in clinical practice. ( Bannister, A; Day, SL; Fisher, M; Hankins, M; Leake Date, HA, 2005)
"The article demonstrates that in drug addicted patients joining of viral infections (HIV hepatitis) results in increase of content of total and direct bilirubin, alanine aminotransferase and aspartate aminotransferase and in decrease of content of urea."3.78[The blood biochemical indicators in drug addicted patients with HIV-infection and viral hepatitis]. ( Arsent'eva, LA; Borodulin, VB; Bychkov, EN; Korshunov, GV; Serkova, SA, 2012)
"Tenofovir disoproxil fumarate (TDF) has been anecdotally associated with isolated hypophosphatemia (HP) as well as proximal tubular toxicity and renal dysfunction in which HP has consistently been a feature."3.73Serum hypophosphatemia in tenofovir disoproxil fumarate recipients is multifactorial in origin, questioning the utility of its monitoring in clinical practice. ( Bannister, A; Day, SL; Fisher, M; Hankins, M; Leake Date, HA, 2005)
"Differences in disease progression occurred from the third year on ART, whereas higher rates of switch to second-line treatment occurred in LCM from the second year."2.75Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. ( Abaine, D; Aber, M; Ahimbisibwe, F; Akao, J; Akuma, S; Amuron, B; Amurwon, J; Angweng, E; Anywar, W; Atwiine, D; Atwiine, S; Awio, P; Babiker, A; Babiker, AG; Bafana, T; Bagaya, L; Bahendeka, S; Bakeinyaga, GT; Barungi, G; Bassett, M; Bohannon, J; Boocock, K; Borok, M; Bray, D; Breckenridge, A; Bulaya-Tembo, R; Buluma, E; Burke, A; Burke, C; Byakwaga, H; Byamukama, A; Byaruhanga, R; Chakonza, L; Chidziva, E; Chigwedere, E; Chimanzi, J; Chimbetete, C; Chirairo, H; Chirara, M; Chirema, O; Chitsungo, S; Chivhunga, T; Coutinho, A; Darbyshire, JH; Drasiku, A; Dunn, D; Enzama, R; Etukoit, B; Fadhiru, K; Ferrier, A; Florence, A; Foster, S; Gazzard, B; Generous, L; Gibb, DM; Gilks, C; Gilks, CF; Goodall, R; Grosskurth, H; Grundy, C; Haguma, W; Hakim, J; Hill, C; Hughes, P; Jamu, A; Jangano, M; Jones, S; Kabanda, J; Kabuye, G; Kagina, G; Kajungu, D; Kaleebu, P; Kambungu, A; Kankunda, R; Karungi, J; Kasirye, R; Katabira, E; Katabira, H; Katundu, P; Khauka, P; Kigozi, J; Kikaire, B; Kityo, C; Komugyena, J; Kulume, R; Kusiima, A; Kyomugisha, H; Labeja, O; Lara, AM; Latif, A; Levin, J; Lubwama, E; Lutwama, F; Lyagoba, F; Machingura, I; Machingura, J; Makota, S; Mambule, I; Mapinge, F; Mapuchere, C; Massa, R; Matenga, J; Matongo, M; Maweni, C; Mawora, A; McCormick, A; McLaren, A; Mdege, N; Moyo, K; Muchabaiwa, L; Mudzingwa, S; Mufuka-Kapuya, C; Muganzi, A; Mugisha, A; Mugurungi, O; Mugyenyi, P; Muhweezi, D; Muhwezi, A; Mukiibi, S; Mukose, A; Mulindwa, G; Mulindwa, M; Munderi, P; Murungi, S; Musana, H; Musoro, G; Mutowo, J; Mutsai, S; Muvirimi, C; Muyingo, S; Muzambi, M; Mwebesa, D; Mwesigwa, P; Nabankema, E; Nabongo, P; Naidoo, B; Nairuba, R; Nakahima, W; Nakazibwe, M; Nakiyingi, J; Nalumenya, R; Namale, L; Namara, W; Namata, I; Namazzi, A; Namuli, T; Namyalo, M; Nanfuka, A; Nanfuka, R; Nassuna, G; Ndembi, N; Newland, C; Ngorima, N; Nimwesiga, E; Nsibambi, D; Nyachwo, L; Nyiraguhirwa, D; Ochai, R; Ojiambo, H; Ojiambo, W; Oketta, F; Omony, W; Otim, T; Oyugi, J; Palfreeman, A; Pascoe, M; Pearce, G; Peto, L; Peto, T; Phiri, M; Pillay, D; Pozniak, A; Puddephatt, C; Rahim, S; Rauchenberger, M; Reid, A; Robertson, V; Ronald, A; Rooney, J; Ruberantwari, A; Rutikarayo, N; Sabiiti, J; Sadik, F; Sematala, F; Serwadda, D; Sheehan, S; Simango, M; Smith, M; Snowden, W; Spencer-Drake, C; Spyer, M; Ssali, F; Steens, JM; Svovanapasis, P; Takubwa, J; Taylor, K; Taziwa, F; Tinago, G; Todd, J; Tugume, S; Tukamushaba, J; Tumukunde, D; Tumusiime, C; Twijukye, C; Vere, L; Waita, R; Wakholi, BN; Walker, AS; Walusimbi, J; Wangati, K; Wanyama, J; Wapakhabulo, AC; Warambwa, C; Warara, R; Wavamunno, P; Weller, I; Whitworth, J; Wilkes, H; Winogron, D; Yirrell, D; Zalwango, A; Zalwango, E; Zawedde, C; Zengeza, E, 2010)
" Forty-nine patients received the elixir or SEDDS at a dosage of 750 mg three times daily or 1125 mg twice daily for 14 days."2.68Phase I/II study of the toxicity, pharmacokinetics, and activity of the HIV protease inhibitor SC-52151. ( Fischl, MA; Flexner, C; Haubrich, R; Holden-Wiltse, J; Karim, A; Meehan, PM; Para, MF; Richman, DD; Yeramian, P, 1997)
" While the use of currently approved HIV protease inhibitors in concert with drugs that target the reverse transcriptase has dramatically ameliorated the disease state for many individuals, highly-structured dosing regimens accompanied by adverse side-effect profiles have led to a significant level of patient non-compliance."2.42Non-peptidic HIV protease inhibitors. ( Chrusciel, RA; Strohbach, JW, 2004)
" Syndecan-1 may be a useful early biomarker to monitoring renal dysfunction in HIV patients in chronic use of cART."1.46Endothelial Glycocalyx Damage and Renal Dysfunction in HIV Patients Receiving Combined Antiretroviral Therapy. ( Cavalcante, MG; da Silva Junior, GB; De Francesco Daher, E; Libório, AB; Martins, AMC; Meneses, GC; Neto, RDJP, 2017)
"Sera from 30 patients with systemic lupus erythematosus (SLE), but without features of anti-phospholipid syndrome (APS) (SLE/non APS), six with SLE and secondary APS, (SLE/APS) and 11 with primary APS (PAPS) were also evaluated as controls."1.30Anti-phospholipid antibodies in HIV infection and SLE with or without anti-phospholipid syndrome: comparisons of phospholipid specificity, avidity and reactivity with beta2-GPI. ( Kordossis, T; Moutsopoulos, HM; Petrovas, C; Vlachoyiannopoulos, PG, 1999)

Research

Studies (38)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's6 (15.79)18.2507
2000's11 (28.95)29.6817
2010's15 (39.47)24.3611
2020's6 (15.79)2.80

Authors

AuthorsStudies
Kaviani, A1
Khansari Nejad, N1
Akour, A1
AlMuhaissen, SA1
Nusair, MB1
Al-Tammemi, AB1
Mahmoud, NN1
Jalouqa, S1
Alrawashdeh, MN1
Shanahan, JP1
Moore, CM1
Kampf, JW1
Szymczak, NK1
Guo, J1
Wang, H1
Luo, Y1
An, H1
Zhang, Z2
Liu, G1
Li, J2
Metcalfe, GD1
Smith, TW1
Hippler, M1
Ayala Izurieta, JE1
Márquez, CO1
García, VJ1
Jara Santillán, CA1
Sisti, JM1
Pasqualotto, N1
Van Wittenberghe, S1
Delegido, J1
Kubo, Y1
Kitagawa, Y1
Miyazaki, T1
Sohda, M1
Yamaji, T1
Sakai, M1
Saeki, H1
Nemoto, K1
Oyama, T2
Muto, M1
Takeuchi, H1
Toh, Y1
Matsubara, H1
Mano, M1
Kono, K1
Kato, K1
Yoshida, M1
Kawakubo, H1
Booka, E1
Yamatsuji, T1
Kato, H1
Ito, Y1
Ishikawa, H1
Ishihara, R1
Tsushima, T1
Kawachi, H1
Kojima, T1
Kuribayashi, S1
Makino, T1
Matsuda, S1
Doki, Y1
Ma, P1
Tang, X1
Zhang, L2
Wang, X1
Wang, W1
Zhang, X1
Wang, S2
Zhou, N1
Dodd, J1
Jordan, R1
Makhlina, M1
Pesco Koplowitz, L1
Koplowitz, B1
Barnett, K1
Yang, WH1
Spana, C1
Buchanan, SW1
Mafa-Attoye, T1
Dunfield, K1
Thevathasan, NV1
Isaac, ME1
Wu, X2
Huang, JW1
Su, BK1
Yuan, L1
Zheng, WQ1
Zhang, H2
Zheng, YX1
Zhu, W1
Chou, PT1
Manso, AP1
De Morais, DC1
Yamamoto, K1
Owen, G1
de Carvalho, RM1
Palma-Dibb, RG1
Brown, JC1
Yang, S1
Mire, EF1
Miele, L1
Ochoa, A1
Zabaleta, J1
Katzmarzyk, PT1
Moi, CT1
Bhowmick, S1
Qureshi, M1
Wang, K1
Feng, B1
Yang, Y1
Chen, Y1
Wang, Y2
Yang, L1
Jiang, K1
James, TD1
Chaturvedi, V1
Postiglione, WM1
Chakraborty, RD1
Yu, B1
Tabiś, W1
Hameed, S1
Biniskos, N1
Jacobson, A1
Zhou, H1
Greven, M1
Ferry, VE1
Leighton, C1
Wu, F1
Lei, H1
Chen, G1
Chen, C1
Song, Y1
Cao, Z1
Zhang, C2
Zhou, J1
Lu, Y1
Pappone, C1
Santinelli, V1
Mecarocci, V1
Tondi, L1
Ciconte, G1
Manguso, F1
Sturla, F1
Vicedomini, G1
Micaglio, E1
Anastasia, L1
Pica, S1
Camporeale, A1
Lombardi, M1
Shieh, PB1
Elfring, G1
Trifillis, P1
Santos, C1
Peltz, SW1
Parsons, JA1
Apkon, S1
Darras, BT1
Campbell, C1
McDonald, CM1
Galaviz, KI1
Shah, NS1
Gutierrez, M1
Collins, LF1
Lahiri, CD1
Moran, CA1
Szabo, B1
Sumitani, J1
Rhodes, J1
Marconi, VC1
Nguyen, ML1
Cantos, VD1
Armstrong, WS1
Colasanti, JA1
Olusola, BA1
Kabelitz, D1
Olaleye, DO1
Odaibo, GN1
Jerebtsova, M1
Ahmad, A1
Niu, X1
Rutagarama, O1
Nekhai, S1
Tabassum, T1
Azeem, SM1
Muwonge, AN1
Frey, KM1
Lu, X1
Zhang, M2
Liu, W1
Sheng, N1
Du, Q1
Guo, X1
Wang, G1
Wang, Q1
Vazquez, T1
Zarei, M1
Herskovitz, I1
Price, A1
Villada, G1
Keri, J1
Johnson, J1
Zhai, Y1
Salimi, H1
Espy, N1
Eichelberger, N1
DeLeon, O1
O'Malley, Y1
Courter, J1
Smith, AB1
Madani, N1
Sodroski, J1
Haim, H1
Giacobbi, NS1
Sluis-Cremer, N1
Pang, X1
Liu, Z1
Zhai, G1
Chitra, P1
Bakthavatsalam, B1
Palvannan, T1
Ugaonkar, SR1
Wesenberg, A1
Wilk, J1
Seidor, S1
Mizenina, O2
Kizima, L1
Rodriguez, A1
Zhang, S2
Levendosky, K1
Kenney, J2
Aravantinou, M2
Derby, N1
Grasperge, B1
Gettie, A2
Blanchard, J2
Kumar, N1
Roberts, K1
Robbiani, M3
Fernández-Romero, JA3
Zydowsky, TM3
Villegas, G1
Calenda, G1
Kleinbeck, K1
Cooney, ML1
Hoesley, CJ1
Creasy, GW1
Friedland, B1
Teleshova, N1
Radhika, V1
Jaraf, HA1
Kanth, SS1
Vijjulatha, M1
Meneses, GC1
Cavalcante, MG1
da Silva Junior, GB1
Martins, AMC1
Neto, RDJP1
Libório, AB1
De Francesco Daher, E1
Parboosing, R1
Paruk, I1
Lalloo, UG1
Lapinski, TW1
Parfieniuk, A1
Rogalska-Plonska, M1
Czajkowska, J1
Flisiak, R1
Roan, NR1
Sowinski, S1
Münch, J1
Kirchhoff, F1
Greene, WC1
Mugyenyi, P3
Walker, AS2
Hakim, J3
Munderi, P2
Gibb, DM2
Kityo, C2
Reid, A2
Grosskurth, H3
Darbyshire, JH3
Ssali, F2
Bray, D2
Katabira, E4
Babiker, AG1
Gilks, CF1
Kabuye, G1
Nsibambi, D2
Kasirye, R1
Zalwango, E1
Nakazibwe, M1
Kikaire, B1
Nassuna, G1
Massa, R1
Fadhiru, K2
Namyalo, M1
Zalwango, A1
Generous, L1
Khauka, P2
Rutikarayo, N1
Nakahima, W1
Mugisha, A1
Todd, J1
Levin, J1
Muyingo, S1
Ruberantwari, A1
Kaleebu, P2
Yirrell, D2
Ndembi, N2
Lyagoba, F2
Hughes, P1
Aber, M1
Lara, AM2
Foster, S2
Amurwon, J2
Wakholi, BN2
Whitworth, J1
Wangati, K1
Amuron, B1
Kajungu, D1
Nakiyingi, J1
Omony, W1
Tumukunde, D1
Otim, T1
Kabanda, J1
Musana, H1
Akao, J1
Kyomugisha, H1
Byamukama, A1
Sabiiti, J1
Komugyena, J1
Wavamunno, P1
Mukiibi, S1
Drasiku, A1
Byaruhanga, R1
Labeja, O1
Katundu, P2
Tugume, S2
Awio, P1
Namazzi, A1
Bakeinyaga, GT1
Katabira, H1
Abaine, D1
Tukamushaba, J1
Anywar, W1
Ojiambo, W1
Angweng, E1
Murungi, S2
Haguma, W1
Atwiine, S1
Kigozi, J3
Namale, L1
Mukose, A1
Mulindwa, G1
Atwiine, D1
Muhwezi, A1
Nimwesiga, E1
Barungi, G1
Takubwa, J1
Mwebesa, D1
Kagina, G1
Mulindwa, M1
Ahimbisibwe, F1
Mwesigwa, P1
Akuma, S1
Zawedde, C1
Nyiraguhirwa, D1
Tumusiime, C1
Bagaya, L1
Namara, W1
Karungi, J1
Kankunda, R1
Enzama, R1
Latif, A2
Robertson, V2
Chidziva, E1
Bulaya-Tembo, R1
Musoro, G1
Taziwa, F1
Chimbetete, C1
Chakonza, L1
Mawora, A1
Muvirimi, C1
Tinago, G1
Svovanapasis, P1
Simango, M1
Chirema, O1
Machingura, J1
Mutsai, S1
Phiri, M1
Bafana, T1
Chirara, M2
Muchabaiwa, L2
Muzambi, M2
Mutowo, J1
Chivhunga, T1
Chigwedere, E1
Pascoe, M1
Warambwa, C1
Zengeza, E1
Mapinge, F1
Makota, S1
Jamu, A1
Ngorima, N1
Chirairo, H1
Chitsungo, S1
Chimanzi, J1
Maweni, C1
Warara, R1
Matongo, M1
Mudzingwa, S1
Jangano, M1
Moyo, K1
Vere, L1
Mdege, N1
Machingura, I1
Ronald, A1
Kambungu, A1
Lutwama, F1
Mambule, I1
Nanfuka, A1
Walusimbi, J1
Nabankema, E1
Nalumenya, R1
Namuli, T1
Kulume, R1
Namata, I1
Nyachwo, L1
Florence, A1
Kusiima, A1
Lubwama, E1
Nairuba, R1
Oketta, F1
Buluma, E1
Waita, R1
Ojiambo, H1
Sadik, F1
Wanyama, J1
Nabongo, P1
Oyugi, J1
Sematala, F1
Muganzi, A1
Twijukye, C1
Byakwaga, H1
Ochai, R1
Muhweezi, D1
Coutinho, A1
Etukoit, B1
Gilks, C2
Boocock, K1
Puddephatt, C1
Grundy, C1
Bohannon, J1
Winogron, D1
Burke, A1
Babiker, A2
Wilkes, H1
Rauchenberger, M1
Sheehan, S1
Spencer-Drake, C1
Taylor, K1
Spyer, M1
Ferrier, A1
Naidoo, B1
Dunn, D2
Goodall, R2
Peto, L1
Nanfuka, R1
Mufuka-Kapuya, C1
Pillay, D1
McCormick, A1
Weller, I1
Bahendeka, S1
Bassett, M1
Wapakhabulo, AC1
Gazzard, B1
Mapuchere, C1
Mugurungi, O1
Burke, C1
Jones, S1
Newland, C1
Pearce, G1
Rahim, S1
Rooney, J1
Smith, M1
Snowden, W1
Steens, JM1
Breckenridge, A1
McLaren, A1
Hill, C1
Matenga, J1
Pozniak, A1
Serwadda, D1
Peto, T1
Palfreeman, A1
Borok, M1
Crostarosa, F1
Akpogheneta, OJ1
Jasny, E1
Shaw, A1
Piatak, M1
Lifson, JD1
Teitelbaum, A1
Hu, L1
Chudolij, A1
Mertenskoetter, T1
Kaptur, PE1
Uglietti, A1
Maserati, R2
Korshunov, GV1
Bychkov, EN1
Arsent'eva, LA1
Serkova, SA1
Borodulin, VB1
Lori, F1
De Forni, D1
Baev, D1
Calarota, SA1
Cahn, P1
Testori, M1
Rakhmanova, A1
Stevens, MR1
Yadav, D1
Paliwal, S1
Yadav, R1
Pal, M1
Pandey, A1
Sussman, F1
Villaverde, MC1
Martínez, L1
Kostiushov, VV1
Chrusciel, RA1
Strohbach, JW1
Day, SL1
Leake Date, HA1
Bannister, A1
Hankins, M1
Fisher, M1
Rubinstein, A1
Thorn, M1
Turville, SG1
Titchen, K1
Sudol, K1
Miller, T1
Maguire, RA1
Buckheit, RW1
Hartman, TL1
Phillips, DM1
Rincón, S1
Cepero de García, MC1
Espinel-Ingroff, A1
Mulligan, K1
Grunfeld, C1
Hellerstein, MK1
Neese, RA1
Schambelan, M1
Paton, NI1
Elia, M1
Jebb, SA1
Jennings, G1
Macallan, DC1
Griffin, GE1
Fischl, MA1
Richman, DD1
Flexner, C1
Para, MF1
Haubrich, R1
Karim, A1
Yeramian, P1
Holden-Wiltse, J1
Meehan, PM1
Rayner, MM1
Cordova, B1
Jackson, DA1
Petrovas, C1
Vlachoyiannopoulos, PG1
Kordossis, T1
Moutsopoulos, HM1
Gold, D1
Loftus, R1
Korach, M1
Leclercq, P1
Péronnet, F1
Leverve, X1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The Evaluation of Anti-interference Ability and Clinical Specificity of HIV Ag +Ab Assay Kit (Sysmex)[NCT05983536]1,200 participants (Anticipated)Observational2023-09-20Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

6 reviews available for urea and HIV Coinfection

ArticleYear
    Biomaterial investigations in dentistry, 2021, Volume: 8, Issue:1

    Topics: Adult; Alcohol Drinking; Ammonia; Animals; Anti-Inflammatory Agents; Area Under Curve; B-Lymphocytes

2021
Advances in non-peptidomimetic HIV protease inhibitors.
    Current medicinal chemistry, 2014, Volume: 21, Issue:17

    Topics: Drug Design; Drug Resistance, Viral; Fullerenes; HIV; HIV Infections; HIV Protease; HIV Protease Inh

2014
Update on microbicide research and development - seeking new HIV prevention tools for women.
    European journal of medical research, 2011, Jan-27, Volume: 16, Issue:1

    Topics: Adenine; Administration, Intravaginal; Adult; Africa South of the Sahara; Anti-HIV Agents; Anti-Infe

2011
Antiviral hyperactivation-limiting therapeutics as a novel class for the treatment of HIV/AIDS: focus on VS411.
    Expert opinion on investigational drugs, 2011, Volume: 20, Issue:4

    Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocyte

2011
Non-peptidic HIV protease inhibitors.
    Current topics in medicinal chemistry, 2004, Volume: 4, Issue:10

    Topics: Anti-HIV Agents; Disulfides; Drug Resistance, Viral; Furans; Heterocyclic Compounds, 4 or More Rings

2004
Preclinical studies of alkylureas as anti-HIV-1 contraceptive.
    Current pharmaceutical design, 2005, Volume: 11, Issue:29

    Topics: Administration, Intravaginal; Anti-HIV Agents; Carcinogenicity Tests; Contraceptive Agents, Female;

2005

Trials

4 trials available for urea and HIV Coinfection

ArticleYear
In Vitro Exposure to PC-1005 and Cervicovaginal Lavage Fluid from Women Vaginally Administered PC-1005 Inhibits HIV-1 and HSV-2 Infection in Human Cervical Mucosa.
    Antimicrobial agents and chemotherapy, 2016, Volume: 60, Issue:9

    Topics: Administration, Intravaginal; Anti-Infective Agents; Body Fluids; Coinfection; Female; Gels; Herpes

2016
Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial.
    Lancet (London, England), 2010, Jan-09, Volume: 375, Issue:9709

    Topics: Adenine; Adolescent; Adult; Africa; Aged; Anemia; Anti-Retroviral Agents; CD4 Lymphocyte Count; Crea

2010
VS411 reduced immune activation and HIV-1 RNA levels in 28 days: randomized proof-of-concept study for antiviral-hyperactivation limiting therapeutics.
    PloS one, 2012, Volume: 7, Issue:10

    Topics: Adult; Analysis of Variance; Anti-HIV Agents; Biomarkers; CD4 Lymphocyte Count; CD4-Positive T-Lymph

2012
Phase I/II study of the toxicity, pharmacokinetics, and activity of the HIV protease inhibitor SC-52151.
    Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association, 1997, May-01, Volume: 15, Issue:1

    Topics: Adult; CD4 Lymphocyte Count; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle A

1997

Other Studies

28 other studies available for urea and HIV Coinfection

ArticleYear
Early HIV infection is associated with reduced proportions of gamma delta T subsets as well as high creatinine and urea levels.
    Scandinavian journal of immunology, 2020, Volume: 91, Issue:5

    Topics: Adult; Biomarkers; Creatinine; Female; HIV Infections; Humans; Immunophenotyping; Kidney Diseases; L

2020
HIV-1 Transcription Inhibitor 1E7-03 Restores LPS-Induced Alteration of Lung Leukocytes' Infiltration Dynamics and Resolves Inflammation in HIV Transgenic Mice.
    Viruses, 2020, 02-12, Volume: 12, Issue:2

    Topics: Animals; Cytokines; HIV Infections; HIV-1; Indoles; Inflammation; Lipopolysaccharides; Lung; Macroph

2020
Application of Structure-based Methods to Analyze Resistance Mutations for Chemically Diverse Non-Nucleoside Reverse Transcriptase Inhibitors.
    Current HIV research, 2020, Volume: 18, Issue:4

    Topics: Allosteric Site; Anti-HIV Agents; Binding Sites; Drug Resistance, Viral; Enzyme Assays; Gene Express

2020
A method to alleviate false-positive results of the Elecsys HIV combi PT assay.
    Scientific reports, 2021, 01-13, Volume: 11, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; AIDS Serodiagnosis; Blotting, Western; Child; Child, Pre

2021
Atypical familial aquagenic syringeal acrokeratoderma.
    Journal of cutaneous pathology, 2020, Volume: 47, Issue:11

    Topics: Eccrine Glands; Female; HIV Infections; Humans; Keratoderma, Palmoplantar; Male; Middle Aged; Qualit

2020
Induction of a Tier-1-Like Phenotype in Diverse Tier-2 Isolates by Agents That Guide HIV-1 Env to Perturbation-Sensitive, Nonnative States.
    Journal of virology, 2017, 08-01, Volume: 91, Issue:15

    Topics: Antibodies, Neutralizing; Biomimetics; CD4 Antigens; Cold Temperature; env Gene Products, Human Immu

2017
    Antimicrobial agents and chemotherapy, 2017, Volume: 61, Issue:7

    Topics: Anti-HIV Agents; Drug Resistance, Viral; HIV Infections; Humans; Pyridines; Pyrimidines; Reproductiv

2017
Osteonecrosis with renal damage in HIV patients undergoing HAART.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2014, Volume: 68, Issue:7

    Topics: Antiretroviral Therapy, Highly Active; Arthritis, Rheumatoid; Creatinine; Cystatin C; HIV Infections

2014
A novel intravaginal ring to prevent HIV-1, HSV-2, HPV, and unintended pregnancy.
    Journal of controlled release : official journal of the Controlled Release Society, 2015, Sep-10, Volume: 213

    Topics: Administration, Intravaginal; Animals; Antiviral Agents; Carrageenan; Cell Line; Contraceptive Agent

2015
Integrating Multiple Receptor Conformation Docking and Multi Dimensional QSAR for Enhancing Accuracy of Binding Affinity Prediction.
    Current computer-aided drug design, 2017, Volume: 13, Issue:2

    Topics: Computer-Aided Design; Crystallography, X-Ray; Drug Discovery; HIV Infections; HIV Protease; HIV Pro

2017
Endothelial Glycocalyx Damage and Renal Dysfunction in HIV Patients Receiving Combined Antiretroviral Therapy.
    AIDS research and human retroviruses, 2017, Volume: 33, Issue:7

    Topics: Adolescent; Adult; Anti-Retroviral Agents; Brazil; Creatinine; Cross-Sectional Studies; Endothelial

2017
Hepatitis C virus seropositivity in a South African Cohort of HIV co-infected, ARV naïve patients is associated with renal insufficiency and increased mortality.
    Journal of medical virology, 2008, Volume: 80, Issue:9

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Comorbidity; Creatinine; Female; Hepacivirus; Hepatitis

2008
Prevalence of cryoglobulinaemia in hepatitis C virus- and hepatitis C virus/human immunodeficiency virus-infected individuals: implications for renal function.
    Liver international : official journal of the International Association for the Study of the Liver, 2009, Volume: 29, Issue:8

    Topics: Adult; Creatinine; Cryoglobulinemia; Cryoglobulins; Cystatin C; Early Diagnosis; Female; Glomerular

2009
Aminoquinoline surfen inhibits the action of SEVI (semen-derived enhancer of viral infection).
    The Journal of biological chemistry, 2010, Jan-15, Volume: 285, Issue:3

    Topics: Aminoquinolines; Amyloid; Animals; Anti-HIV Agents; Cell Line; Dose-Response Relationship, Drug; Gen

2010
A macaque model to study vaginal HSV-2/immunodeficiency virus co-infection and the impact of HSV-2 on microbicide efficacy.
    PloS one, 2009, Nov-30, Volume: 4, Issue:11

    Topics: Animals; Anti-Infective Agents; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Chlorocebus

2009
[The blood biochemical indicators in drug addicted patients with HIV-infection and viral hepatitis].
    Klinicheskaia laboratornaia diagnostika, 2012, Issue:7

    Topics: Alanine Transaminase; Aspartate Aminotransferases; Bilirubin; Hepatitis; HIV Infections; Humans; Liv

2012
Identification of novel HIV 1--protease inhibitors: application of ligand and structure based pharmacophore mapping and virtual screening.
    PloS one, 2012, Volume: 7, Issue:11

    Topics: Catalytic Domain; Databases, Factual; Drug Design; Guanidines; HIV Infections; HIV Protease; HIV Pro

2012
Modified solvent accessibility free energy prediction analysis of cyclic urea inhibitors binding to the HIV-1 protease.
    Protein engineering, 2002, Volume: 15, Issue:9

    Topics: Binding Sites; HIV Infections; HIV Protease; HIV Protease Inhibitors; Humans; Models, Molecular; Pro

2002
[Clinical significance of parameters of the thiol-dependent mechanism of the biochemical phase of interaction between serum proteins and urea in HIV-infection].
    Klinicheskaia laboratornaia diagnostika, 2003, Issue:7

    Topics: Acquired Immunodeficiency Syndrome; Blood Proteins; Disulfides; HIV Infections; HIV Seropositivity;

2003
Serum hypophosphatemia in tenofovir disoproxil fumarate recipients is multifactorial in origin, questioning the utility of its monitoring in clinical practice.
    Journal of acquired immune deficiency syndromes (1999), 2005, Mar-01, Volume: 38, Issue:3

    Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Blood Chemical Analysis; Creatinine

2005
Carrageenan/MIV-150 (PC-815), a combination microbicide.
    Sexually transmitted diseases, 2007, Volume: 34, Issue:1

    Topics: Anti-Infective Agents; Carrageenan; Chondrus; Drug Therapy, Combination; HIV Infections; HIV-1; HIV-

2007
A modified Christensen's urea and CLSI broth microdilution method for testing susceptibilities of six Malassezia species to voriconazole, itraconazole, and ketoconazole.
    Journal of clinical microbiology, 2006, Volume: 44, Issue:9

    Topics: AIDS-Related Opportunistic Infections; Antifungal Agents; Culture Media; Dermatomycoses; HIV Infecti

2006
Anabolic effects of recombinant human growth hormone in patients with wasting associated with human immunodeficiency virus infection.
    The Journal of clinical endocrinology and metabolism, 1993, Volume: 77, Issue:4

    Topics: Adult; Analysis of Variance; Blood Glucose; Emaciation; Energy Metabolism; Growth Hormone; HIV Infec

1993
Total energy expenditure and physical activity measured with the bicarbonate-urea method in patients with human immunodeficiency virus infection.
    Clinical science (London, England : 1979), 1996, Volume: 91, Issue:2

    Topics: Adult; Calorimetry, Indirect; Carbon Dioxide; Energy Metabolism; HIV Infections; Humans; Male; Middl

1996
Population dynamics studies of wild-type and drug-resistant mutant HIV in mixed infections.
    Virology, 1997, Sep-15, Volume: 236, Issue:1

    Topics: Alkynes; Azepines; Benzoxazines; Cyclopropanes; Drug Resistance, Microbial; HIV; HIV Infections; HIV

1997
Anti-phospholipid antibodies in HIV infection and SLE with or without anti-phospholipid syndrome: comparisons of phospholipid specificity, avidity and reactivity with beta2-GPI.
    Journal of autoimmunity, 1999, Volume: 13, Issue:3

    Topics: Adult; Anti-HIV Agents; Antibodies, Anticardiolipin; Antibody Affinity; Antibody Specificity; Antiph

1999
Protease inhibitors: where are they now?
    GMHC treatment issues : the Gay Men's Health Crisis newsletter of experimental AIDS therapies, 1995, Volume: 9, Issue:1

    Topics: Animals; Blood Proteins; CD4 Lymphocyte Count; Clinical Trials as Topic; Drug Industry; Drug Resista

1995
Metabolic response to a C-glucose load in human immunodeficiency virus patients before and after antiprotease therapy.
    Metabolism: clinical and experimental, 2002, Volume: 51, Issue:3

    Topics: Adult; Blood Glucose; C-Peptide; Calorimetry, Indirect; Carbon Isotopes; Fats; Fatty Acids, Nonester

2002